Liver cancer study reveals which organs respond best to drug combo
NCT ID NCT04862949
First seen Jan 05, 2026 · Last updated May 02, 2026 · Updated 21 times
Summary
This study looked at 131 people with advanced liver cancer to see how a combination of two drugs (atezolizumab and bevacizumab) affects tumors in different parts of the body. The goal was to understand why some tumors shrink and others don't, especially in the liver. Researchers measured tumor size changes in each organ to find patterns that could improve future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cha Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea
Conditions
Explore the condition pages connected to this study.